Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Affecting the Risk of Infection01:26

Factors Affecting the Risk of Infection

The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Acute Inflammation III: Local and Systemic Effects01:25

Acute Inflammation III: Local and Systemic Effects

Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimating GFR Using Creatinine, Cystatin C, or Both and the Impact on Predicted Vancomycin Half-Life.

The Annals of pharmacotherapy·2025
Same author

Executive Summary-Society of Critical Care Medicine and American Society of Health-System Pharmacists Guideline for the Prevention of Stress-Related Gastrointestinal Bleeding in Critically Ill Adults.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2025
Same author

Risk Factors for Stress-related Upper Gastrointestinal Bleeding: More Than a Gut Feeling.

American journal of respiratory and critical care medicine·2025
Same author

Executive Summary-Society of Critical Care Medicine Guideline and American Society of Health-System Pharmacists for the Prevention of Stress-Related Gastrointestinal Bleeding in Critically Ill Adults: Erratum.

Critical care medicine·2025
Same author

The Canadian journal of hospital pharmacy·2025
Same author

Advancing Climate Care in Health Care: Pharmacy's Green Light.

The Canadian journal of hospital pharmacy·2025
Same journal

Correction: VExUS score: optimizing its use in perioperative and critical care management.

Critical care (London, England)·2026
Same journal

Optimizing β-lactam antibiotics with the highest concentration-for continuous infusion reduce carbon footprint in intensive care.

Critical care (London, England)·2026
Same journal

Physiological and clinical effects of selected airway clearance techniques in mechanically ventilated adult ICU patients: a systematic review and synthesis without meta-analysis.

Critical care (London, England)·2026
Same journal

How we use the neurological pupil index (NPi).

Critical care (London, England)·2026
Same journal

45th International Symposium on Intensive Care & Emergency Medicine.

Critical care (London, England)·2026
Same journal

High-resolution monitoring reveals fragmented 24-hour light exposure in intensive care units.

Critical care (London, England)·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

A Data-Driven Approach to Quantifying Immune States in Sepsis
07:42

A Data-Driven Approach to Quantifying Immune States in Sepsis

Published on: February 7, 2025

Immunosedation: a consideration for sepsis.

Robert MacLaren1

  • 1University of Colorado Denver School of Pharmacy, Academic Office 1, C238-L15, 12631 East 17th Avenue, Aurora, CO 80045, USA. rob.maclaren@ucdenver.edu

Critical Care (London, England)
|November 6, 2009
PubMed
Summary
This summary is machine-generated.

Dexmedetomidine and midazolam reduce pro-inflammatory mediators in sepsis models, with varying effects. Both sedatives lowered short-term mortality, suggesting distinct immunomodulatory profiles for clinical consideration.

More Related Videos

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
07:30

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

Related Experiment Videos

Last Updated: Jun 19, 2026

A Data-Driven Approach to Quantifying Immune States in Sepsis
07:42

A Data-Driven Approach to Quantifying Immune States in Sepsis

Published on: February 7, 2025

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
07:30

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

Area of Science:

  • Critical Care Medicine
  • Immunology
  • Pharmacology

Background:

  • Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection.
  • Sedatives are commonly used in sepsis management, but their immunomodulatory effects are not fully understood.

Discussion:

  • Dexmedetomidine and midazolam differentially modulated pro-inflammatory mediators in a rat sepsis model.
  • Dexmedetomidine demonstrated a greater ability to limit apoptosis compared to midazolam.
  • Both sedatives significantly reduced short-term mortality relative to saline treatment.

Key Insights:

  • Sedatives possess distinct immunomodulatory properties beyond their sedative effects.
  • The choice of sedative in sepsis may influence patient outcomes due to these immunomodulatory differences.
  • Further clinical research is needed to validate these findings in human sepsis patients.

Outlook:

  • Future clinical trials should investigate the impact of sedative immunomodulatory profiles on sepsis patient outcomes.
  • Development of sedatives with specific immunosedative profiles could optimize sepsis treatment.
  • Personalized sedation strategies based on immunomodulatory effects may emerge for sepsis management.